These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38011415)

  • 21. Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.
    Hashemi-Meshkini A; Zekri HS; Karimi-Yazdi H; Zaboli P; Sahraian MA; Nikfar S
    Iran J Neurol; 2018 Jul; 17(3):123-128. PubMed ID: 30886679
    [No Abstract]   [Full Text] [Related]  

  • 22. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT
    Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
    Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.
    Keshavarz K; Kebriaeezadeh A; Alavian SM; Akbari Sari A; Rezaei Hemami M; Lotfi F; Hashemi Meshkini A; Javanbakht M; Keshvari M; Nikfar S
    Hepat Mon; 2016 Sep; 16(9):e37435. PubMed ID: 27822262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
    Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
    Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
    Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
    Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Lasalvia P; Hernández F; Castañeda-Cardona C; Cuestas JA; Rosselli D
    Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
    Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
    Nakhaipour HR; Vudumula U; Khurana V; Sébire G; Mah JK; Pohl D; Schecter R; Adlard N
    J Med Econ; 2020 Dec; 23(12):1525-1533. PubMed ID: 33079578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Auguste P; Colquitt J; Connock M; Loveman E; Court R; Ciccarelli O; Counsell C; Armoiry X
    Pharmacoeconomics; 2020 Jun; 38(6):527-536. PubMed ID: 32048205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
    Yousefi M; Rezaei S; Khoshbaten M; Sarmasti M
    Helicobacter; 2023 Dec; 28(6):e13027. PubMed ID: 37839058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y; Wang Y; Wong SL; Yang D; Sundar M; Tundia N
    Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.